haematologica
Journal of the Ferrata Storti Foundation

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials

by Celia González-Gil, Mireia Morgades, Thaysa Lopes, Francisco Fuster-Tormo, Pau Montesinos, Pere Barba, Marina Díaz-Beya, Lourdes Hermosín, Clara Maluquer, José González-Campos, Teresa Bernal, Marta Sitges Arriaga, Lurdes Zamora, Marta Pratcorona, Rodrigo Martino, María José Larrayoz, Teresa Artola, Anna Torrent, Ferran Vall-llovera, Mar Tormo, Cristina Gil, Andrés Novo, Pilar Martínez-Sánchez, Jordi Ribera, María-Paz Queipo, Teresa González-Martínez, Mónica Cabrero, Antonia Cladera, José Cervera, Alberto Orfao, Josep Maria Ribera, and Eulàlia Genescà

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials

Celia González-Gil [1], Mireia Morgades [2ⓧ], Thaysa Lopes [1ⓧ], Francisco Fuster-Tormo [1¥], Pau Montesinos [3], Pere Barba [4], Marina Díaz-Beya [5], Lourdes Hermosín [6], Clara Maluquer [7], José González-Campos [8], Teresa Bernal [9], Marta Sitges Arriaga [10], Lurdes Zamora [2], Marta Pratcorona [11], Rodrigo Martino [11], María José Larrayoz [12], Teresa Artola [13], Anna Torrent [2], Ferran Vall-llovera [14], Mar Tormo [15], Cristina Gil [16], Andrés Novo [17], Pilar Martínez-Sánchez [18], Jordi Ribera [1], María-Paz Queipo [19], Teresa González-Martínez [20], Mónica Cabrero [20], Antonia Cladera [21], José Cervera [3], Alberto Orfao [22], Josep Maria Ribera [1,2], Eulàlia Genescà [1*]

ⓧ Equally contribution

¥ Present address: Technology & Development team. Veritas Intercontinental. Barcelona, Spain

[1]Institut d'Investigació contra la Leucemia Josep Carreras (IJC), Campus ICO-Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.

[2]Departament d'Hematologia Clínica, ICO-Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain.

[3]Hospital Universitari i Politècnic La Fe, Valencia, Spain.

[4]Servei Hematologia Clínica, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain.

[5]Servei Hematologia Clínica, Hospital Clínic de Barcelona, Barcelona, Spain.

[6]Servicio Hematología Clínica, Hospital de Jerez, Jerez de la Frontera, Spain.

[7]Servei Hematologia Clínica, Hospital Duran i Reynals-ICO, Hospitalet del Llobregat, Spain.

[8]Servicio Hematología Clínica, Hospital Virgen del Rocío, Sevilla, Spain.

[9]Servicio Hematología Clínica, Hospital Central de Asturias, Instituto de Investigación Sanitario del Principado de Asturias (ISPA), Instituto Oncológico Universitario del Principado de Asturias (IUOPA), Oviedo, Spain.

[10]Institut Català d'Oncologia (ICO), Hospital Josep Trueta, Girona, Spain.

[11]Servei Hematologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

[12]Laboratorio Enfermedades Hematológica, CIMA, Navarra, Spain.

[13]Servicio Hematología Clínica, Hospital Universitario de Donostia, Spain.

[14]Servei Hematologia Clínica, Hospital Mútua de Terrassa, Spain.

[15]Hospital Clínico Universitario, Instituto de investigación INCLIVA, Valencia, Spain.

[16]Servicio Hematología Clínica, Hospital General de Alicante, Spain.

[17]Servicio Hematología Clínica, Hospital Son Espases, Palma de Mallorca, Spain.

[18]Servicio Hematología Clínica, Hospital 12 de Octubre, Madrid, Spain.

[19]Servicio Hematología Clínica, Hospital Virgen de la Victoria, Málaga, Spain.

[20]Servicio Hematología Clínica, Hospital Universitario de Salamanca, Spain.

[21]Servicio Hematología Clínica, Hospital Son Llátzer, Palma de Mallorca, Spain.

[22]Centro de Investigación del Cáncer (IBMCC-CSIC/USAL) and Departamento de Medicina, Universidad de Salamanca, Instituto Biosanitario de Salamanca, CIBERONC, Salamanca, Spain.

Corresponding author:

*Eulàlia Genescà Ferrer

T-ALL Team-ALL Research Group

Josep Carreras Leukaemia Research Institute (IJC)

Campus Can Ruti, Cami de les Escoles s/n

08916, Badalona, Barcelona

SPAIN

Tel: +34935572800 (Ext. 4150)

egenesca@carrerasresearch.org

Authors' disclosures

The authors declare no competing financial interests.

Data sharing statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous disease characterized by a complex multistep mutagenic process in which different alterations cooperate to transform T-cell precursors. However, the clinical impact of most of these alterations remains unclear, which partly explains why T-ALL subtypes are still defined on morphological and immunophenotypic grounds in the current World Health Organization (WHO) 2022 classification. Here, we used SNP-arrays to investigate the frequency of common copy number variations (CNV), and integrated the results obtained with single nucleotide variants (SNV)/indels data on the same homogeneously treated T-ALL cohort, to evaluate their impact on disease outcome.

A total of 146 T-ALL samples were previously analyzed by target deep sequencing[1]. From those, 134 patients were further studied by SNP-arrays to identify CNV (CytoScan[TM] HD, Thermo Fisher). Samples and clinical data were obtained and stored in accordance with the declaration of Helsinki. The study was approved by the Institutional Review Board of the Hospital Germans Trias i Pujol. CNV and SNV results were integrated to assess their prognostic value in a group of 107 patients, homogeneously enrolled in two consecutive Spanish PETHEMA trials[2,3]. Only recurrent alterations found in ≥5 patients were considered. Patient's characteristics at diagnosis and follow-up are summarized in Table 1.

Focusing on SNP-array data, among patients with CNV, 124/130 (95.4%) had deletions (del) and 72/130 (55.4%) duplications (dup), 66/130 (50.8%) showing a combination of both events (Figure S1). There were CNV targeting a single T-ALL driver gene (*LEF1*, *CDK6*, *PTPN2*, *ELF1*, *WT1*, *TET2*, *PHF6*, and *MYB*). The smallest alteration identified was the deletion of *LEF1* (22 kbp). Other recurrent alterations were heterogeneous in size and afected multiple genes (Figure S2A). In turn, for another subset of alterations the minimum altered region overlapped with a T-ALL driver gene, suggesting that this would be the target gene of the alteration (Figure S2B-M). Other recurrent and larger CNV detected included del(5q), del(6q), dup(5p) and dup(17q) (Figure S2N-Q). Finally, alterations resulting in *STIL::TAL1* (Figure S2R) and *NUP214::ABL1* (Figure S2S) fusions, as well as trisomy of chromosomes 10 and 19, and gains of chromosome X, were also observed.

Among patients with complete genomic data (n=134), 88.8% (119/134) had both SNV and CNV (Figure S1) with a median of 5 alterations/patient [range 1-13]. The frequency and distribution of recurrently identified alterations are in concordance to those previously reported in another adult cohort (Figure 1A)[4]. Notably, there were patients with concomitant SNV/indels and CNV affecting *DNMT3A*, *PTEN*, *FBXW7*, *TET2*, *TP53*, *CTCF* and *RPL5* genes, suggesting that a double-hit event was required for these genes to drive leukemogenesis in T-ALL (Figure 1A).

To evaluate how genetic events cooperate to develop T-ALL in a specific context, we assessed pairwise associations between mutated genes identified in the same patient. We observed co-occurrence of *RB1* with i) *BCL11B* (OR=13.3, q=0.008), ii) *CDKN2A/B* (OR=102 q=0.07) and iii) *NOTCH1* (OR=92.3, q=0.07) alterations. *BCL11B* gene alterations coexisted with i) *NOTCH1* (OR=169.4, q=0.003) and ii) *CDKN2A/B* (OR=17, q=0.01) alterations. *STIL::TAL1* gene fusion co-occurred with del(6q) (OR=7.1, q=0.09). The strongest association was found between *JAK3* and *JAK1* mutations (OR=115, q=0.003)[5]. *JAK3* was also frequently mutated in patients with *PHF6* mutations (OR=5.1, q=0.09)[6]. Moreover, mutual exclusion was observed between *CDKN2A/B* and *DNMT3A* alterations (OR= 0.09, q= 0.01) (Figure 1B, left panel).

From the immunophenotypic point of view, *CDKN1B, CDKN2A/B, RB1* deletions and *MYB* duplications were more frequently observed among cortical T-ALL (OR=10.6, q=0.003; OR=4.8, q=0.005; OR=10.3, q=0.02; OR=7.8, q=0.07 respectively). Conversely, *N/KRAS* mutations and cortical immunophenotype were mutually exclusive (OR= 0.1, q= 0.07). These mutations were co-occurrent with the ETP-ALL immunophenotype (OR=4.7, q=0.07)[1], similarly like *DNMT3A* and *RUNX1* alterations (OR=8, q=0.01; OR=5.6, q=0.06, respectively). In turn, *CDKN2A/B, BCL11B* and *FBXW7* mutations (OR=0.04, q=9×10^{-6}; OR=0, q=0.07; OR= 0.1, q=0.07, respectively), were mutually exclusive with ETP-ALL (Figure 1B, right panel).

To infer the potential sequence of acquisition of the different genetic events, we used VAF, CN values and tumor cell contents to calculated the cancer cell fraction (CCF) for each sample. All patients had at least one clonal alteration, defined by a CCF > 50% (Figure 1C). The median CCF of the CNV was higher than that of SNV/indels (1 [0.15-1] versus 0.83 [0.04-1], p<0.0001), indicating earlier occurrence of the former. In fact, only two genes altered by CNV had more than 35% of their variants as subclonal, *CDK6* and *CTCF* (Figure 1C, left panel). In case of SNV, a large number of genes presented subclonal variants (*IL7R, KMT2C, PTEN, BCL11B, NOTCH1* and *JAK1*), suggesting a later acquisition of these events, according to the CCF model[7] (Fig. 1C, right panel). Similarly, the clonal profile of *PTEN* varied according to the type of alteration, with CNV having higher CCF than SNV/indels (1 [0.4-1] versus 0.51 [0.08-1], p=0.001).

Subsequently, we explored potential genetic-clinical correlations based on a total of 44 different genetic subgroups (Table 2 & Table S1). Thus, we focused on those alterations that affected >5 patients (Figure 1A) and their correlation with T-ALL biological features at diagnosis, treatment response and survival data. We excluded genes that were only affected by SNV, because their prognostic impact had been previously investigated[1]. In parallel, we also evaluated the clinical impact of the statistically significant pairwise associations described above (Figure 1B). Finally, we assessed the impact of genetic complexity, defined as the sum of SNV & CNV per patient.

Regarding individual alterations, del(5q) (n=8) and *ETV6* gene alterations (*ETV6^{alt}*, 4 SNV and 2 CNV) had an impact on OS, while alterations in *TP53* (*TP53^{alt}*, 4 CNV, 1 SNV plus CNV) showed a trend (Table 2). Of note, patients with del(5q) showed worse response to treatment: slower response after 14 days of induction (≥ 10% blasts) (100% of deleted patients versus 40% of non-deleted, p=0.005), lower complete remission (CR) rates even, after two cycles of induction therapy (50% of deleted patients versus 91% of non-deleted, p=0.008), resulting in an increase of deaths during induction therapy (62.5 % of deleted patients versus 5.7% of non-deleted, p=0.0002). Such an adverse response and outcome was also observed among patients with *DNMT3A/ N/KRAS/ MSH2/ U2AF1* SNV, collectively defined as variable as the worse outcome genetic profile (WOG), previously described for the same study cohort[1]. In fact, 6/8 patients with del(5q) had WOG mutations and consequently, patients with both alterations (WOG + del(5q)) exhibited significantly shorter OS compared to those with only WOG mutations (median OS of 0.16 [0.02-NA] versus 0.81 [0.45-1.75], p< 0.001), emphasizing the deleterious effect of an additional del(5q) in the WOG patient group.

In T-ALL, the prognostic significance of *PTEN* alterations remains controversial. Our results showed that neither *PTEN* CNV nor SVN nor CNV plus SNV had an impact on patient outcome (Table S1), consistent with previous studies[8,9]. Thereby, the genetic signature *NOTCH1/FBXW7^{wt}* and/or *N/KRAS^{mut}* and/or *PTEN^{alt}* did not have prognostic value in our series (data not shown), and, therefore, our results do not validate the genetic score proposed by Trinquand A *et al.*[10] to stratify adult T-ALL patients.

Regarding the clinical impact of pairwise genetic associations, we observed that patients with deletions in *CDKN2A/B* genes and cortical immunophenotype exhibited a trend for better OS (Table 2). Finally, patients with a complex tumor genome, defined as >14 alterations (14^{alt}), had poorer OS (Table 2) and lower CR rates (68.8% patients with >14^{alt} achieved CR versus 97.8% of patients with ≤14^{alt}, p=0.002).

Overall, our results suggest that CNV seem to cooperate with specific SNV/indels, delineating recurrent onco-genetic pathways that define the transformation of each T-cell precursor at a particular stage of differentiation. Thus, alterations in *RB1*, *BCL11B*, *CDK1NB* lead to a T-cell transformation at a cortical thymocyte, while *N/KRAS* mutations, *DNMT3A* or *RUNX1* alterations, would block the T-cell differentiation process at an earlier stage (ETP-ALL). Based on these findings, we would not expect CNV to substantially improve the risk stratification provided by immunophenotypic groups[11]. Interesting, we observed that patients with *CDKN2A/B* gene deletions and a cortical immunophenotype had a trend for better outcomes.

We have also shown that some CNV identify patients with poor outcome. That is the case of del(5q), the CNV with the highest impact on OS in our cohort. Del(5q) has been previously

described in a small cohort of adult T-ALL patients to be associated with an immature immunophenotype and the presence of stem cell/myeloid markers[12]. Most patients showed a WOG signature that mainly identifies patients with ETP-ALL and advanced age[1], which might explain their poorer outcome. We could not validate the impact, previously shown, of $TP53^{alt}$ in this cohort[13], due to the limited number of positive cases, although we see a trend to worse outcome. The limited number of patients with $ETV6^{alt}$ also abort the possibility to assess their outcome.

We also studied the value of genomic complexity to stratify adult T-ALL patients, based on the number of CNV & SNV per patient, which could provide information of the plasticity of blast cell. We showed that an increased number of $>14^{alt}$ was associated with worse outcomes, similarly to what has been described with karyotype studies[14,15]. This may be due to the higher genetic heterogeneity of leukemic cells in these patients, which provides more opportunities for the leukemia to evade treatment. However, limitations in the cohort size, precluded the evaluation of the prognostic impact of this genetic marker by multivariable analysis.

In summary, herein we show that CNV, that are essential for T-cell leukemia development, help to improve genetic risk stratification of T-ALL. Further studies in larger T-ALL cohorts with complete genomic data (i.e. inclusion of rearrangements) are needed to confirm our findings and to delineate an integrative genetic approach to assess clinically relevant onco-genetic pathways.

REFERENCES

1. González-Gil C, Morgades M, Lopes T, et al. Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials. Haematologica. 2023;108(4):969-980.

2. Ribera J-M, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595-1604.

3. Ribera J-M, Morgades M, Ciudad J, et al. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. Blood. 2021;137(14):1879-1894.

4. Van Vlierberghe P, Ambesi-Impiombato A, De Keersmaecker K, et al. Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. Blood. 2013;122(1):74-82.

5. Degryse S, de Bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-3100.

6. Yuan S, Wang X, Hou S, et al. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. Leukemia. 2022;36(2):370-382.

7. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313.

8. Zuurbier L, Petricoin EF, Vuerhard MJ, et al. The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia. Haematologica. 2012;97(9):1405-1413.

9. Jenkinson S, Kirkwood AA, Goulden N, Vora A, Linch DC, Gale RE. Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial. Leukemia. 2016;30(1):39-47.

10. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013;31(34):4333-4342.

11. Jain N, Lamb AV, O'Brien S, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127(15):1863-1869.

12. La Starza R, Barba G, Demeyer S, et al. Deletions of the long arm of chromosome 5 define subgroups of T-cell acute lymphoblastic leukemia. Haematologica. 2016;101(8):951-958.

13. Simonin M, Andrieu GP, Birsen R, et al. Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL. Blood. 2023;141(11):1353-1358.

14. Moorman AV, Harrison CJ, Buck GAN, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189-3197.

15. Genescà E, Morgades M, González-Gil C, et al. Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). Leuk Res. 2021;109:106612.

TABLES

Table 1. Clinical and biological characteristics, response to treatment and outcome of T-cell acute lymphoblastic leukemia patients (n=107)*.

Patient-related features		
Median age, y [range]		37 [16-61]
Gender, M/F		79/28
Biologic features		
Cytogenetics	< 3 alterations	59/107 (55%)
	≥ 3 alterations	10/107 (9%)
	NE	38/107 (36%)
Immunophenotype	ETP-ALL	20/102 (20%)
	Pre-T	18/102 (18%)
	Cortical	42/102 (41%)
	Mature	22/102 (21%)
Disease-related features		
Median WBC, $x10^9$/L [range]		52.8 [0.5-525.4]
ECOG score	0	40/103 (39%)
	1	49/103 (47%)
	2	12/103 (12%)
	≥3	2/103 (2%)
Adenopathy		49/90 (54%)
Splenomegaly		36/102 (35%)
Hepatomegaly		25/101 (25%)
Mediastinal mass		44/104 (42%)
CNS involvement		14/110 (13%)
Response-related features		
Slow response on day +14		44/91 (48%)
N. of induction cycles to CR	1	87 (81%)
	2	20 (19%)
CR post Ind-1		87 (81%)
CR (Ind-1 + Ind-2)		96 (87%)
MRD <0.1% on day +35		68/81 (84%)

Post consolidation treatment	Chemotherapy	54/74 (73%)
	Allo-SCT	20/74 (27%)
Outcome features		
OS prob. (95% CI) at 5 years		37 (27-48)
CIR (95% CI) at 5 years		54 (43-64)

*27/134 initial patients were excluded (1 pediatric; 3 intermediate risk; 4 older; 14 patients treated with an ongoing trial; and 4 without clinical data). Results expressed as number of cases/total cases (percentage) when not otherwise indicated. +MRD values were considered for those patients that reached CR. Y: years; M: male; F: female; NE: non-evaluable; ETP-ALL: early T-cell precursor acute lymphoblastic leukemia; WBC: white blood cell count; CNS: central nervous system; CR: complete remission; MRD: measurable residual disease; d+14: fourteen days after induction treatment; d+35: thirty-five days after induction treatment; Allo-SCT: allogeneic stem cell transplantation; OS: overall survival; CIR: cumulative incidence of relapse; CI: confidence interval.

Table 2. Prognostic impact of genetic alterations and associations in the adult T-ALL cohort

Alteration	Frequency of alteration		Time point OS prob. (years)	OS (95% CI)		p value
	Patients with alteration (%)	Patients without alteration (%)		Patients with alteration	Patients without alteration	
Del(5q)	8/114 (7)	106/114 (93)	*	0.17 (0.02-0.74)	2.02 (1.53-4.88)	<0.001
ETV6^{alt}	6/107 (5.6)	101/107 (94.4)	5	67 (5-95)	35 (25-46)	0.041
TP53^{alt}	5/107 (4.7)	102/107 (95.3)	*	0.11 (0.05-0.17)	2.02 (0.7-3.32)	0.100
Cortical** & CDKN2A/B	33/102 (32.4)	69/102 (67.6)	5	50 (40-60)	34 (27-41)	0.12
Nº alt > 14***	16/107 (15)	91/107 (85)	5	26 (14-38)	40 (34-46)	0.006

* results are expressed as median of OS due to most patients do not reach one year of OS; OS: overall survival; CI: confidence interval. Alt: alterations (sum of SNV/indel & CNV). OS was estimated using Kaplan-Meier method. ** p value= 0.189 for OS of cortical vs no-cortical patients. *** We used the maxstat test (R test) to determine that a cut-off of 14 alterations was the most significant threshold to stratify the patients according their OS.

FIGURE LEGENDS

Figure 1. Genetic profile of adult T-ALL at diagnosis. (A) Mutational landscape of adult T-ALL patients. Only alterations found in at least 5 patients are shown. Genes affected by both SNV/indel and CNV in the same patient are highlighted in brown. (B) Pairwise associations between altered genes identified in the same patient (left panel) and between genetic alterations and immunophenotype (right panel). Associations are shown only for alterations present in at least 10 patients. Combinations were tested using the Fisher test corrected by the Benjamini-Hochberg multiplicity test (considering significant coexistence when q<0.1). Positive correlations are represented by the blue range color and negative correlations by the red range color. (C) Box and whisker representation of cancer cell fractions (CCF) for CNV (left panel) and SNV/indels (right panel). The threshold to define clonality (0.5) is indicated by the dashed line. All statistical analyses were performed using SPSS version 24 (IBM Corp. Armonk, NY), GraphPad Prism® version 10 (GraphPad Software Inc., La Jolla, CA) and R version 4.1.0. SNV: single nucleotide variant; CNV: copy number variation.

A

GENE	FRACTION	FREQ
NOTCH1	91/146	62.3%
CDKN2A/B	81/134	60.4%
PHF6	31/146	21.2%
FBXW7	28/146	19.2%
PTEN	28/146	19.2%
BCL11B	21/146	14.4%
JAK3	19/146	13.0%
del(6q)	19/134	14.2%
CDKN1B	18/146	12.3%
RUNX1	17/146	11.6%
CTCF	17/146	11.6%
NKRAS	16/146	11.0%
DNMT3A	15/146	10.3%
FAT1	15/146	10.3%
RB1	13/134	9.7%
STIL::TAL1	13/134	9.7%
JAK1	11/146	7.5%
DNM2	11/146	7.5%
MYB	11/134	8.2%
RPL22	11/134	8.2%
IL7R	10/146	6.8%
ETV6	10/146	6.8%
LEF1	10/146	6.8%
RPL5	10/146	6.8%
EP300	9/146	6.2%
del(5q)	9/134	6.7%
PTPN2	8/134	6.0%
CDK6	8/134	6.0%
WT1	8/146	5.5%
CREBBP	8/146	5.5%
del(19p13.2)	8/134	6.0%
GATA3	7/146	4.8%
Trisomy 10	7/134	5.2%
Trisomy 19	7/134	5.2%
TP53	6/146	4.1%
KMT2C	6/146	4.1%
MSH2	6/146	4.1%
dup(17q)	6/134	4.5%
dup(5q)	6/134	4.5%
ELF1	5/134	3.7%
TET2	5/146	3.4%
FAT3	5/146	3.4%
U2AF1	5/146	3.4%
NUP214::ABL1	5/134	3.7%
del(19p13.3)	5/134	3.7%
del(12p13.2p12.1)	5/134	3.7%
Gain of Chr X	5/134	3.7%

SNV/indel
Loss (CNV)
Gain (CNV)
Double hit

B

Pairwise gene associations

Pairwise gene-inmunophenotype associations

Mutually exclusive — Co-mutant
Log 10 (Odds ratio)
<-2.2   0   <+2.5

***q<0.01
**q<0.05
*q<0.1

C

CCF_CNVs

CCF_SNVs

SNV/indel
Loss (CNV)
Gain (CNV)

Table S1. Prognostic impact of genetic alterations and associations assessed in the adult T-ALL cohort

Alteration/ Genetic Association	Frequency of alteration		Time point OS prob. (years)	OS (CI95%)		p value
	Patients with alteration (%)	Patients without alteration (%)		Patients with alteration	Patients without alteration	
CDKN2A/B (CNV)	67/107 (62.6)	40/107 (37.4)	5	40 (27-53)	31 (14-50)	0.50
PHF6 (SNV & CNV)	28/107 (26.2)	81/107 (75.7)	5	47 (25-66)	36 (24-48)	0.99
FBXW7 (SNV & CNV)	23/108 (21.3)	85/108 (78.7)	5	51 (25-72)	34 (22-46)	0.13
PTEN (SNV & CNV)	22/109 (20.2)	87/109 (79.8)	5	30 (9-55)	38 (26-50)	0.85
PTEN (SNV)	13/116 (11.2)	103/116 (88.9)	5	27(5-58)	38 (27-49)	0.92
PTEN (CNV)	12/107 (11.2)	95/107 (88.8)	5	46 (17-71)	36 (25-48)	0.97
BCL11B (SNV & CNV)	18/107 (16.8)	89/107 (83.2)	5	35 (12-60)	38 (26-50)	0.49
del(6q) (CNV)	16/107 (15.0)	91/107 (85.0)	5	46 (21-69)	36 (24-47)	0.73
CDKN1B (SNV & CNV)	14/107 (13.1)	93/107 (86.9)	5	44 (16-69)	36 (25-48)	0.56
RPL22 (CNV)	14/107 (13.1)	93/107 (86.9)	4	17 (1-50)	42 (31-53)	0.17
CTCF (SNV & CNV)	13/107 (12.1)	94/107 (87.9)	5	35 (9-63)	38 (26-49)	0.85
RUNX1 (SNV & CNV)	11/107 (10.3)	96/107 (89.7)	5	49 (16-75)	36 (25-47)	0.72
RPL5 (SNV & CNV)	10/108 (9.3)	98/108 (90.7)	5	37 (6-69)	38 (26-49)	0.92
RB1 (CNV)	10/107 (9.3)	97/107 (90.7)	5	40 (10-70)	37 (26-49)	0.41
MYB (CNV)	10/107 (9.3)	97/107 (90.7)	5	39 (7-71)	37 (26-48)	0.63
PTPN2 (CNV)	8/107 (7.5)	99/107 (92.5)	5	73 (28-93)	34 (23-45)	0.19
ELF1 (CNV)	8/107 (7.5)	99/107 (92.5)	2	50 (15-78)	50 (39-60)	0.62
STIL-TAL1 (CNV)	7/107 (6.5)	100/107 (93.5)	5	54 (13-83)	36 (25-47)	0.41
WT1 (SNV & CNV)	7/107 (6.5)	100/107 (93.5)	5	51 (12-81)	36 (25-47)	0.37
LEF1 (SNV & CNV)	6/107 (5.6)	101/107 (94.4)	5	44 (7-79)	37 (26-48)	0.89
CREBBP (SNV & CNV)	6/107 (5.6)	101/107 (94.4)	4	17 (1-52)	42 (31-52)	0.15
Trisomy 10 (CNV)	6/107 (5.6)	101/107 (94.4)	5	67 (20-90)	35 (24-46)	0.43
del(19p13.2) (CNV)	5/107 (4.7)	102/107 (95.3)	3	30 (1-72)	45 (35-55)	0.88
del(19p13.3) (CNV)	5/107 (4.7)	102/107 (95.3)	5	33 (1-77)	37 (26-48)	0.31
dup(5q) (CNV)	5/107 (4.7)	102/107 (95.3)	3	60 (13-88)	44 (33-54)	0.85
NUP214-ABL1 (CNV)	5/107 (4.7)	102/107 (95.3)	5	40 (5-75)	38 (27-49)	0.80
Gain of X (CNV)	5/107 (4.7)	102/107 (95.3)	5	27 (1-69)	38 (27-49)	0.55
Trisomy 19 (CNV)	5/107 (4.7)	102/107 (95.3)	5	60 (13-88)	36 (26-47)	0.70
RB1 & BCL11B	7/107 (6.5)	100/107 (93.5)	5	34 (0-72)	38 (27-49)	0.56

RB1 & **CDKN2A/B**	10/107 (9.3)	97/107 (90.7)	5	40 (10-70)	37 (26-49)	0.41
RB1 & **NOTCH1**	10/107 (9.3)	97/107 (90.7)	5	40 (10-70)	37 (26-49)	0.41
BCL11B & **NOTCH1**	18/107 (16.8)	89/107 (83.2)	5	35 (12-60)	38 (26-50)	0.49
BCL11B & **CDKN2A/B**	17/107 (15.9)	90/107 (84.1)	5	30 (17-43)	40 (28-52)	0.70
JAK3 & JAK1	8/107 (7.5)	99/107 (92.6)	5	37 (17-57)	38 (32-44)	0.80
JAK3 & PHF6	9/107 (8.4)	98/107 (91.6)	5	26 (10-42)	38 (32-44)	0.26
ETP-ALL & **N/KRAS**	6/108 (5.6)	102/108 (94.4)	5	33 (13-53)	40 (34-46)	0.45
Cortical & RB1	9/102 (9.7)	93/102 (91.2)	5	47 (28-66)	40 (34-46)	0.42
Cortical & **CDKN1B**	12/102 (11.8)	90/102 (88)	5	52 (36-68)	38 (32-44)	0.3

Results for alterations and genetic associations affecting ≥ 5 are shown. Results expressed as median of OS; SNV: single nucleotide variant; CNV: copy number variation. OS: overall survival; CI: confidence interval.

SUPPLEMENTARY FIGURE LEGEND

Figure S1. Genetic study flow-Chart. Distribution of patients included in the study cohort according to the alterations detected by TDS and SNP-arrays. SNV functional impact classification was defined according to previously reported criteria[1]. TDS: Target Deep Sequencing; SNP: Single Nucleotide Polymorphism; SNV: Single Nucleotide Variant; CNV: Copy Number Variation.

Figure S2. CNV and subgroups: Size and positions of the different alterations are shown for the different groups. (A) del(12p): each subgroup defined according to the affected deleted genes are represented in different colours. Position of deleted T-ALL driver genes is indicated by a dash line with an arrow. (B) del(13p): each subgroup defined according to the deleted genes are represented in different colours. Position of *RB1* is indicated by a dash line with an arrow. (C) del(16q): position of *CTCF* is indicated by a dash line with an arrow. (D) del(1)(p32.3;p36.33): position of *RPL22* is delimited by lines and highlighted in yellow. (E) del(1)(p11.2;p31.1): position of *RPL5* is indicated by a dash line with an arrow. (F) del(16p): position of *CREBBP* is indicated by a dash line with an arrow. (G) del(17p): position of *TP53* is indicated by a dash line with an arrow. (H) del(4)(q31.3): position of *FBXW7* is delimited by lines and highlighted in yellow. (I) del(10)(q23): position of *PTEN* is delimited by lines and highlighted in yellow. (J) del(14)(q32.2): position of *BLC11B* is delimited by lines and highlighted in yellow. (K) del(21)(q22.12): position of *RUNX1* is delimited by lines and highlighted in yellow. (L) del(19)(p13.2): position of *DNM2* and *SMARCA4* are indicated by a line and the genes are highlighted in yellow. (M) del(19)(p13.3): the name of the gene is highlighted in yellow. (N) del(5q). (O) del(6q). (P) dup(5p). (Q) dup(17q). (R) *STIL::TAL1* gene fusion. (S) *NUP214::ABL1* gene fusion. Losses are represented in red and gains in blue. CNVs and immunophenotype correlations found were: i) del(9p) affecting *CDKN2A/B* genes, del(12p) involving *CDKN1B* with or without *ETV6* deletions (Figure S1A), but not *KRAS,* and del(13q) restricted to *RB1* gene (Figure S1B), were associated with the cortical immunophenotype (OR=4.5, p=0.0002; OR= 7.6, p=0.0006; OR=7.3, p=0.002, respectively); ii) del(16q) involving *CTCF* (Figure S1C), was associated with a mature immunophenotype (OR=3.9; p=0.03).